Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689087 | 0.93 | TSPO (0.41) | TSPOPLA2G2AHTR6FABP4 | |
| SCHEMBL6691740 | 0.93 | PLA2G2A (0.44) | TSPOPLA2G2AHTR6 | |
| SCHEMBL27844993 | 0.91 | FABP4 (0.37) | TSPOHTR6FABP4FABP3 | |
| SCHEMBL818609 | 0.90 | PLA2G2A (0.47) | PLA2G2A | |
| SCHEMBL29862385 | 0.90 | PLA2G2A (0.47) | PLA2G2A | |
| SCHEMBL6697582 | 0.90 | PLA2G2A (0.44) | TSPOPLA2G2AHTR6FABP4FABP3 | |
| SCHEMBL6694139 | 0.90 | TSPO (0.42) | TSPOPLA2G2AHTR6FABP4HCRTR1 | |
| SCHEMBL8371555 | 0.89 | PLA2G2A (0.46) | PLA2G2A | |
| SCHEMBL6129588 | 0.88 | FABP4 (0.36) | TSPOPLA2G2AHTR6FABP4FABP3 | |
| SCHEMBL6691162 | 0.88 | TSPO (0.44) | TSPOPLA2G2AFABP4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0950657-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | LILLY CO ELI (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |